A

Attovia

Clinical-stage biopharma developing biparatopic nanobodies

Head of Investor Relations

Full-Time
$265k - $315k/yr
Expert
Bachelor's, MBA, PhD
San Carlos, CA, USA
In Person
Growth & MarketingPR & Communications

About the job

Requirements
  • A bachelor's degree is required.
  • At least 8 years of relevant experience in investor relations, equity research, investment banking, or corporate finance, including meaningful experience in biotechnology, pharmaceuticals, or life sciences.
  • Strong understanding of financial reporting, valuation methodologies, and capital markets used by investment professionals.
  • Exceptional written and verbal communication skills, strong organization, and meticulous attention to detail and accuracy.
  • Ability to manage multiple priorities in a fast-paced, dynamic environment and deliver polished output under tight deadlines.
Responsibilities
  • Develop and execute an investor relations strategy aligned with corporate objectives, pipeline milestones, and long-term growth ambitions.
  • Manage the current investor relations agency and future public relations or media agency.
  • Serve as the day-to-day point of contact for buy-side and sell-side investors, field investor inquiries, and build relationships with current and prospective shareholders.
  • Partner with agencies to produce investor-facing materials, including press releases, earnings call scripts and question-and-answer preparation, investor presentations, media communications, fact sheets, and the annual report.
  • Partner with the executive team to prepare for and manage quarterly earnings calls, board meetings, investor conferences, medical conferences, non-deal roadshows, and research-and-development-day presentations.
  • Lead proactive and targeted investor outreach, including identifying and cultivating relationships with new institutional investors.
  • Monitor and analyze sell-side analyst research, market activity, shareholder composition, and peer and competitor developments, and deliver regular updates and insights to the executive team and Board.
  • Collaborate with research and development, clinical development, regulatory, legal, and corporate communications teams to ensure accurate, consistent, and compliant messaging across investor touchpoints.
  • Support corporate development activities, including materials related to mergers and acquisitions, partnerships, licensing deals, and capital markets transactions such as follow-on offerings.
  • Manage the corporate website and investor relations section.
  • Ensure compliance with Securities and Exchange Commission regulations, Regulation FD, and other disclosure requirements in coordination with Legal.
  • Build and scale the investor relations function's tools, processes, and infrastructure as the company grows.
Desired Qualifications
  • Experience at a publicly traded biotechnology or pharmaceutical company, including direct experience supporting earnings calls, roadshows, and Securities and Exchange Commission reporting cycles.
  • Scientific fluency and comfort engaging with clinical and regulatory content, with the ability to translate complex science into an accessible investment narrative, especially in autoimmune diseases.
  • Experience with investor-relations-specific tools, such as shareholder identification and customer relationship management platforms and earnings call or webcast providers.
  • A Master of Business Administration, Chartered Financial Analyst credential, or advanced scientific degree.
  • A proven track record of building relationships and influencing across all levels of an organization, including senior executives and the Board.

About the company

Preparing company summary.

Company Size

51-200

Company Stage

IPO

Headquarters

San Carlos, California

Founded

2023

Get referred to Attovia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2, 2026 data showed rapid, deep itch relief across two patient populations.
  • August 2026 IPO raised about $305 million net, funding operations into 2030.
  • Phase 2 starts for ATTO-1310 in 1H 2027; ATTO-2306 enters Phase 1.

What critics are saying

  • Attovia remains pre-revenue; September 2026 cash burn still funds losses, not commercialization.
  • ATTO-1310 carries binary Phase 2 risk in 2027; one failure weakens the platform story.
  • IPO dilution and single-asset dependence make ATTO-1310’s failure an existential company risk.

What makes Attovia unique

  • ATTOBODY nanobodies bind two epitopes, targeting hard GPCRs and cytokines.
  • ATTO-1310 showed 2026 Phase 1b itch relief and 12-week IL-31 suppression.
  • Attovia advanced three candidates in under two years, faster than typical biopharma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

6%
Motoring Malaysia
Aug 31st, 2026
Attovia Therapeutics lists on Nasdaq at $904M valuation to develop immune disease treatments

Attovia Therapeutics, a clinical-stage biopharmaceutical company developing treatments for immune-mediated diseases, listed on Nasdaq on 5 August 2026. The Shanghai-based company issued shares at $17.00 each, opening at $21.00, with a market capitalisation of approximately $904 million. Founded in 2023, Attovia develops biotherapeutics using its ATTOBODY platform, licensed from Alamar Biosciences. The platform enables rapid discovery of monospecific, bispecific and trispecific biologics. The company has nominated three product candidates: ATTO-1310, ATTO-2306 and ATTO-1091. IPO proceeds will fund clinical development of ATTO-1310 and ATTO-2306, plus research pipeline advancement. Attovia is a portfolio company of Qiming Venture Partners, which backed the firm at its early stage. Qiming manages $9.5 billion across eleven US dollar and seven RMB funds.

Attovia Therapeutics, Inc.
Aug 6th, 2026
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Thu, 08/06/2026 - 16:05

SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the closing of its upsized initial

wallstreet:online AG
Aug 5th, 2026
Attovia Therapeutics prices upsized $289M IPO at $17 per share

Attovia Therapeutics, a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases, priced its upsized initial public offering at $17.00 per share. The San Carlos-based company will sell 17,000,000 shares, generating gross proceeds of $289.0 million before underwriting costs and expenses. Attovia has also granted underwriters a 30-day option to purchase up to 2,550,000 additional shares at the offering price. The company's common stock is expected to begin trading on the Nasdaq Global Market on 5 August 2026 under the ticker symbol "ATTO", with the offering closing on 6 August 2026. Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers, whilst LifeSci Capital acts as passive book-running manager.

AInvest Fintech Inc.
Jul 14th, 2026
Goldman Sachs and venBio hold 5%+ stakes in Attovia after $105M Series B

Attovia Therapeutics has disclosed that Venbio Global Strategic Fund IV and Goldman Sachs-affiliated entities each hold 5% or greater stakes in the company. This follows Attovia's oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives with participation from venBio and other investors. Since launching in June 2023, Attovia has raised $165 million in total. The Series B proceeds will advance lead programmes ATTO-1310 and ATTO-002 through initial clinical readouts and further develop its ATTOBODY platform. Goldman Sachs Alternatives appointed Colin Walsh to Attovia's board of directors. VenBio has been a consistent investor since Attovia's inception. The increased ownership reflects investor confidence in Attovia's pipeline and proprietary platform for developing bi-specific therapeutics targeting immune-mediated diseases.

FinSMEs
Apr 16th, 2025
Attovia Therapeutics Raises $90M in Series C Financing

Attovia Therapeutics, a San Carlos, CA-based privately-held, clinical-stage biopharma company, raised $90M in Series C funding